Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on…